



ASX Release

TERMINATION OF LICENCE AGREEMENT

Melbourne, Australia; 19 October 2018

Jayex Healthcare Limited (ASX:JHL) has confirmed that the conditional healthcare technology licence agreement entered into with MediCann NZ Ltd and MediGlobal Ltd on 6 July 2018 has been terminated.

JHL denies MediCann's statement that the termination was due to a conflict of interest and failure to disclose solvency issues and reserves all of its rights.

-Ends-

Contacts for further information:

Media Enquiries

Justin Kelly
Media + Capital Partners
+61 408 215 858
justin.kelly@mcpartners.com.au

Imogen Conyers
Media + Capital Partners
+61 405 191 257
Imogen.conyers@mcpartners.com.au

Investor Enquiries

Chief Executive Officer
Nick Fernando
1300 330 611
n.fernando@jayex.com

Company Secretary
Melanie Leydin
+61 3 9692 7222

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider of integrated healthcare services delivery platforms in the United Kingdom and Australia, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*[®] remote pharmacy prescription processing and dispensing terminal.